EXCiPACT announces that DQS awarded Grace GmbH an EXCiPACT Certificate for its Worms, Germany excipient-manufacturing site.
On June 17, EXCiPACT announced that one of its certification bodies, DQS, awarded Grace GmbH an EXCiPACT Certificate. Grace’s excipient manufacturing facility in Worms, Germany was deemed to meet the expectations of the EXCiPACT GMP certification standards. The certification at this site marks the eighth site to be certified in Germany, and the 20th to be certified worldwide.
Drug manufacturers in the US and the EU must complete individual physical audits or commission a third party to complete an audit of all starting material suppliers to “demonstrate GMP and/or GDP compliance thus increasing the audit burden. Using GMP and GDP standards designed for excipients, the new, high quality third party EXCiPACT Certification Scheme is already helping excipient users and suppliers to reduce their audit burden, save costs, and assure quality,” according to a press release. According to the EXCiPACT website, (http://www.excipact.org/about-us/) the organization was designed to provide excipient manufacturers with certificates to minimize audit burdens and costs in assessing cGMP and cGDP standards throughout the excipient supply chain while maintaining quality and patient safety.
Source: EXCiPACT
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.